“Compliance Shield” Protocol to Deliver Verified, Signed Plaintiffs for Depo-Provera MDL 3140

As the legal industry turns its attention to the rapidly maturing MDL 3140: In re: Depo-Provera Products Liability Litigation, Mohr Marketing announces the immediate availability of a specialized signed case acquisition program.

This new offering allows law firms to build their pharmaceutical liability inventory with pre-vetted, compliant plaintiffs who allege that prolonged use of the contraceptive injection caused them to develop intracranial meningiomas.

With an estimated 74 million users worldwide and a landmark study from the British Medical Journal linking the drug to a 5.6-fold increased risk of brain tumors, the Depo-Provera docket represents a critical opportunity for mass tort firms. However, the medical complexity of these claims requires a higher standard of intake diligence.

Recognizing the unique challenges of establishing specific causation in neurological injury cases, Mohr Marketing has deployed its proprietary Compliance Shield protocol to ensure every signed case meets strict compensability criteria.

The Depo-Provera litigation is not a standard failure-to-warn case; it is a battle over medical specifics. Firms cannot afford to fill their dockets with generic headache complaints or unrelated tumor types like glioblastomas. Our program is designed to deliver signed retainers that have already cleared the hurdles of usage duration and specific tumor diagnosis. We are not just generating leads; we are building defensible dockets.

The Compliance Shield Advantage

Mohr Marketing’s intake process for Depo-Provera cases utilizes a multi-layered defense system to filter out fraud and unqualified claims before they reach a law firm’s inventory.

The protocol includes:

• Usage Duration Verification: Strict screening to ensure the plaintiff used the injection for at least one year (cumulative dose), aligning with the high-risk cohort identified in the March 2024 BMJ study.
• Specific Injury Validation: We do not accept self-reported “brain tumors.” We screen specifically for a diagnosis of Intracranial Meningioma, confirmed by imaging (MRI/CT), while filtering out non-qualifying neurological conditions.
• Timeline & Labeling Checks: Verification that the usage occurred within the actionable window where the alleged failure to warn was most egregious, prior to the FDA’s recent label updates.
• Regulatory Compliance: Integration of Scammer Scrub™ technology to block bot traffic, alongside TrustedForm/Jornaya certification to provide documented proof of consent for every retainer, ensuring full TCPA compliance.

Strategic Docket Growth

With the Northern District of Florida (Judge M. Casey Rodgers) scheduling the first bellwether trials for late 2026, the window for firms to acquire cases at the “ground floor” is open.

Mohr Marketing’s program offers firms a scalable, secure pathway to enter this high-stakes litigation against Pfizer, a defendant with the solvency to support a global settlement.

Law firms interested in acquiring signed Depo-Provera cases or learning more about the Compliance Shield protocol can contact Mohr Marketing directly at https://www.mohrmktg.com

Ready to build your Depo-Provera inventory?

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Best Wishes,
Sue Mohr

Summary

Article Name

"Compliance Shield" Protocol to Deliver Verified, Signed Plaintiffs for Depo-Provera MDL 3140

Description

Recognizing the unique challenges of establishing specific causation in neurological injury cases, Mohr Marketing has deployed its proprietary Compliance Shield protocol to ensure every signed case meets strict compensability criteria.

Author

Susan Mohr

Publisher Name

Mohr Marketing, LLC

Publisher Logo